NASDAQ:ASLN - ASLAN PHARMACEUTICALS ADR REP 5 Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.79 -0.02 (-0.42 %)
(As of 12/13/2018 09:26 AM ET)
Previous Close$4.81
Today's Range$4.50 - $4.99
52-Week Range$4.20 - $10.44
Volume10,820 shs
Average Volume21,747 shs
Market Capitalization$154.04 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in developing therapeutics for global markets. It targets diseases that are highly prevalent in Asia, and orphan indications in the United States and Europe. The company's product pipeline includes Varlitinib, a reversible small molecule pan-human epidermal growth factor receptor inhibitor that is being studied in global pivotal trials (TreeTopp) for biliary tract cancer, and conducting Phase 2/3 clinical trials for gastric cancer, as well as testing in a single-arm pivotal clinical trial in biliary tract cancer in China. It has exclusive global rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. It is also developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase 2 clinical trails to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. The company has partnerships with Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL. ASLAN Pharmaceuticals Limited was founded in 2010 and is headquartered in Singapore.

Receive ASLN News and Ratings via Email

Sign-up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASLN
Previous Symbol
CUSIPN/A
Phone65-6222-4235

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees47
Outstanding Shares32,030,000
Market Cap$154.04 million
OptionableNot Optionable

ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) Frequently Asked Questions

What is ASLAN PHARMACEUTICALS ADR REP 5's stock symbol?

ASLAN PHARMACEUTICALS ADR REP 5 trades on the NASDAQ under the ticker symbol "ASLN."

How were ASLAN PHARMACEUTICALS ADR REP 5's earnings last quarter?

ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ:ASLN) released its earnings results on Thursday, November, 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.34) by $0.27. View ASLAN PHARMACEUTICALS ADR REP 5's Earnings History.

What price target have analysts set for ASLN?

4 analysts have issued 1-year price targets for ASLAN PHARMACEUTICALS ADR REP 5's stock. Their forecasts range from $7.00 to $16.00. On average, they anticipate ASLAN PHARMACEUTICALS ADR REP 5's share price to reach $11.6667 in the next year. This suggests a possible upside of 143.6% from the stock's current price. View Analyst Price Targets for ASLAN PHARMACEUTICALS ADR REP 5.

What is the consensus analysts' recommendation for ASLAN PHARMACEUTICALS ADR REP 5?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASLAN PHARMACEUTICALS ADR REP 5 in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ASLAN PHARMACEUTICALS ADR REP 5.

What are Wall Street analysts saying about ASLAN PHARMACEUTICALS ADR REP 5 stock?

Here are some recent quotes from research analysts about ASLAN PHARMACEUTICALS ADR REP 5 stock:
  • 1. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $382M. This valuation includes a discounted cash flow analysis based asset value of $392M for varlitinib and ASLAN003, using a 15% discount rate and 0.5% terminal growth rate and excluding $10M debt." (12/7/2018)
  • 2. According to Zacks Investment Research, "ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company's product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003 both are in clinical stage. ASLAN Pharmaceuticals Limited is based in Singapore. " (11/9/2018)

Has ASLAN PHARMACEUTICALS ADR REP 5 been receiving favorable news coverage?

Headlines about ASLN stock have trended very positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. ASLAN PHARMACEUTICALS ADR REP 5 earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.

Who are some of ASLAN PHARMACEUTICALS ADR REP 5's key competitors?

Who are ASLAN PHARMACEUTICALS ADR REP 5's key executives?

ASLAN PHARMACEUTICALS ADR REP 5's management team includes the folowing people:
  • Dr. Carl Alan Jason Morton Firth, Chairman & CEO (Age 45)
  • Mr. Kiran Asarpota, VP of Fin. (Age 39)
  • Dr. Mark McHale, Chief Operating Officer (Age 53)
  • Charlie Hsu, Investor Relations Director
  • Mr. Ben Goodger, Gen. Counsel (Age 55)

When did ASLAN PHARMACEUTICALS ADR REP 5 IPO?

(ASLN) raised $60 million in an initial public offering (IPO) on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray served as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

When did the company's lock-up period expire?

ASLAN PHARMACEUTICALS ADR REP 5's lock-up period expired on Wednesday, October 31st. ASLAN PHARMACEUTICALS ADR REP 5 had issued 6,000,000 shares in its IPO on May 4th. The total size of the offering was $42,180,000 based on an initial share price of $7.03. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.

How do I buy shares of ASLAN PHARMACEUTICALS ADR REP 5?

Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ASLAN PHARMACEUTICALS ADR REP 5's stock price today?

One share of ASLN stock can currently be purchased for approximately $4.79.

How big of a company is ASLAN PHARMACEUTICALS ADR REP 5?

ASLAN PHARMACEUTICALS ADR REP 5 has a market capitalization of $154.04 million. ASLAN PHARMACEUTICALS ADR REP 5 employs 47 workers across the globe.

What is ASLAN PHARMACEUTICALS ADR REP 5's official website?

The official website for ASLAN PHARMACEUTICALS ADR REP 5 is http://www.aslanpharma.com.

How can I contact ASLAN PHARMACEUTICALS ADR REP 5?

ASLAN PHARMACEUTICALS ADR REP 5's mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company can be reached via phone at 65-6222-4235 or via email at [email protected]


MarketBeat Community Rating for ASLAN PHARMACEUTICALS ADR REP 5 (NASDAQ ASLN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  53 (Vote Underperform)
Total Votes:  97
MarketBeat's community ratings are surveys of what our community members think about ASLAN PHARMACEUTICALS ADR REP 5 and other stocks. Vote "Outperform" if you believe ASLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2018 by MarketBeat.com Staff

Featured Article: Technical Analysis

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel